Markri-Farma SRL
Markri-Farma reported total assets of €2.60m at the end of the 2025 financial year (annual accounts filed with the NBB on 26 Dec 2025).
The score of Markri-Farma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +1 % Total assets -2 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Markri-Farma's annual accounts
Filed annual accounts
- Year ended 30 Jun 2025filed on 26 Dec 2025
- Year ended 30 Jun 2024filed on 03 Dec 2024
- Year ended 30 Jun 2023filed on 04 Dec 2023
- Year ended 30 Jun 2022filed on 28 Nov 2022
- Year ended 30 Jun 2021filed on 15 Dec 2021
Markri-Farma's financial analysis
- Solvency49.1%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Markri-Farma
Markri-Farma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0817.521.047
- VAT number
- BE0817521047
- Peppol
- Registered · 0208:0817521047 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 03 Aug 2009
- Registered office
- 3020 Herent
- Latest accounts
- 2025 · filed on 26 Dec 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Markri-Farma (SRL) has been based in Herent since 2009, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 161,353 € and equity of €1.28m; its revenue is not published. Its solvency stands at 49.1%, above the median of its sector (44.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Markri-Farma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie de Givry Manufacture of basic pharmaceutical products Quévy · balance sheet €1.30m
- Groupe Tete Pharmaceutical Manufacture of basic pharmaceutical products Nivelles · balance sheet €1.15m
- ANAP Retail sale of pharmaceutical products Aalst · balance sheet €1.37m
- Varmaca Retail sale of pharmaceutical products Peer · balance sheet €2.03m
- K-Farma Retail sale of pharmaceutical products Zandhoven · balance sheet €1.94m
- Braeckevelt-Lafaut Retail sale of pharmaceutical products Bruges · balance sheet €2.44m
- APR.P.D. Retail sale of pharmaceutical products Hasselt · balance sheet €2.05m
- Apotheek Schellekens - Lauwers Retail sale of pharmaceutical products Schelle · balance sheet €1.84m
Frequently asked questions about Markri-Farma
What is the revenue of Markri-Farma?
Markri-Farma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Markri-Farma?
In Belgium, the VAT number is the company number prefixed with BE: BE0817521047 for Markri-Farma, if the company is VAT-registered. Its company number (CBE) is 0817.521.047.
Where is the registered office of Markri-Farma?
According to the CBE register, the registered office of Markri-Farma is in 3020 Herent.
What is the equity of Markri-Farma?
At the close of the 2025 financial year, the equity of Markri-Farma amounts to 1,277,636 €, a solvency of 49.1% of total assets.
Who manages Markri-Farma?
The register lists 2 active mandates at Markri-Farma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Markri-Farma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →